At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 257 enrolled

Drug / intervention

Fluzone Influenza Vaccine (2007-2008)biological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00504231

NCT00504231Phase 2Completed

Compare CT.gov

Intradermal vs. Intramuscular Delivery of Influenza Vaccine in Immunocompetent Elders

PATH·interventional·Posted Jul 19, 2007·Updated Jul 13, 2012

In Brief

A Phase 2 clinical trial evaluating Fluzone Influenza Vaccine (2007-2008) for Influenza. Completed, enrolled 257 participants.

Detailed Summary

This randomized trial compared the immunogenicity of 60% dose intradermal (ID) influenza vaccination to standard intramuscular (IM) vaccination of full-dose or 60% dose vaccine. Pre- and postvaccination measurements in the hemagglutination inhibition antibody (HAI) titer were compared. Participants who received reduced-dose vaccine were revaccinated with full-dose IM vaccine.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsInfluenza

Countries--

CollaboratorsVA Puget Sound Health Care System, Seattle Institute for Biomedical and Clinical Research

Timeline

Phase 2CompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

First PostedJul 2007

Enrollment StartSep 2007

Primary CompletionJan 2008

TodayJul 2026

First PostedJul 19, 2007

Enrollment StartSep 1, 2007

Primary CompletionJan 1, 2008

TodayJul 2, 2026

Enrollment to primary: 4 monthsPosted 19.0 years ago

Interventions

Fluzone Influenza Vaccine (2007-2008)biological

Manufactured by Sanofi Pasteur